Prostate, Phase I-II

A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the safety and efficacy of ARV-766 in men with metastatic castration-resistant prostate cancer.

Contact Information

For more information about this study, including how to volunteer, contact Daniel P. Petrylak

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Principal Investigator